ConductScience.org, home

Paper7514366

Risperidone in the treatment of schizophrenia.

Marder SR and 1 other. Am J Psychiatry, 1994. Cited by 1,080 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Risperidone in the treatment of schizophrenia. Papers, record 7514366. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7514366

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Risperidone in the treatment of schizophrenia.
PubMed
Journal
Am J Psychiatry
PubMed
Year
1994
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
1,080
iCite
Relative citation ratio, by iCite
46.5
iCite
Revised in PubMed
2022-03-18
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Marder SRS R
2Meibach RCR C

Source PubMed

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antipsychotic AgentsMajor topic
IsoxazolesMajor topic
PiperidinesMajor topic
SchizophreniaMajor topic
Adolescent
Adult
Aged
Double-Blind Method
Drug Administration Schedule
Female
Haloperidol
Humans
Male
Middle Aged
Placebos
Psychiatric Status Rating Scales
Risperidone
Schizophrenic Psychology
Treatment Outcome

Source PubMed

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00249132A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic SchizophreniaResultsClinicalTrials.gov
NCT05282277Examining the Effects of Estradiol on Neural and Molecular Response to RewardBackgroundClinicalTrials.gov

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in7,542,836Risperidone for treatment-refractory schizophrenia.https://conductscience.org/library/papers/7542836

Source PubMed

Cited by183

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,080 citations.

PMIDTitleJournalYearIn PapersSource
42,446,851Animal Models for Drug Discovery in Schizophrenia: A Critical View from a Clinical Perspective.Pharmaceut Med2026https://conductscience.org/library/papers/42446851PubMed
42,295,697A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use.CNS Drugs2026https://conductscience.org/library/papers/42295697PubMed
42,282,265The inhibitors of 17β-HSD10: are they any good?RSC Chem Biol2026https://conductscience.org/library/papers/42282265PubMed
42,110,904Efficacy and Safety of Risperidone Microspheres for Injection (II) in Patients With Schizophrenia Spectrum Disorders: A Prospective, Single-Arm, Multicenter Real-World Study.Alpha Psychiatry2026https://conductscience.org/library/papers/42110904PubMed
41,469,509Sex-specific transcriptome similarity networks elucidate comorbidity relationships.Commun Med (Lond)2025https://conductscience.org/library/papers/41469509PubMed
40,561,150Major adverse cardiac events with haloperidol: A meta-analysis.PLoS One2025https://conductscience.org/library/papers/40561150PubMed
40,149,518Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials.Biomedicines2025https://conductscience.org/library/papers/40149518PubMed
39,950,283An Emerging Prospective of Antipsychotics for Treating Neurodegenerative Disorders.Curr Pharm Des2025https://conductscience.org/library/papers/39950283PubMed
39,799,532Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.CNS Drugs2025https://conductscience.org/library/papers/39799532PubMed
39,619,356Modeling Schizophrenia with Glioblastoma Cells: In Vitro Analysis of Risperidone Treatment on Glial Spheroids.Psychiatry Clin Psychopharmacol2021https://conductscience.org/library/papers/39619356PubMed
38,659,603Relationship between plasma risperidone concentrations and clinical features in chronic schizophrenic patients in China.World J Psychiatry2024https://conductscience.org/library/papers/38659603PubMed
38,200,532Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients.BMC Psychiatry2024https://conductscience.org/library/papers/38200532PubMed
37,867,639Piperidine: A Versatile Heterocyclic Ring for Developing Monoamine Oxidase Inhibitors.ACS Omega2023https://conductscience.org/library/papers/37867639PubMed
37,741,946Targeting metacognitive change mechanisms in acute inpatients with psychotic symptoms: feasibility and acceptability of a modularized group intervention.Eur Arch Psychiatry Clin Neurosci2024https://conductscience.org/library/papers/37741946PubMed
36,408,307Risperidone Abruption-Induced Tardive Dyskinesia in a Six-Year-Old Male Patient With Known Autism and Attention Deficit Hyperactivity Disorder: A Case Report.Cureus2022https://conductscience.org/library/papers/36408307PubMed
36,188,551Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update.Front Pharmacol2022https://conductscience.org/library/papers/36188551PubMed
35,904,592Movement disorders of the mouth: a review of the common phenomenologies.J Neurol2022https://conductscience.org/library/papers/35904592PubMed
35,615,642Current and Possible Future Therapeutic Options for Huntington's Disease.J Cent Nerv Syst Dis2022https://conductscience.org/library/papers/35615642PubMed
35,547,105Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital.S Afr J Psychiatr2022https://conductscience.org/library/papers/35547105PubMed
35,137,229Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.Schizophr Bull2022https://conductscience.org/library/papers/35137229PubMed

See all 183 cited by

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
HALOPERIDOLCHEMBL54Results1https://conductscience.org/library/drugs/CHEMBL54ChEMBL
RISPERIDONECHEMBL85Results1https://conductscience.org/library/drugs/CHEMBL85ChEMBL

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7514366

GET https://conductscience.org/api/papers/v1/7514366/cited_by?page=2